Altered myogenesis and premature senescence underlie human TRIM32-related myopathy

E. Servián-Morilla, M. Cabrera-Serrano, E. Rivas-Infante, A. Carvajal, P. J. Lamont, A. L. Pelayo-Negro, G. Ravenscroft, R. Junckerstorff, J. M. Dyke, S. Fletcher, A. M. Adams, F. Mavillard, M. A. Fernández-García, J. L. Nieto-González, N. G. Laing and C. Paradas

Abstract

TRIM32 is a E3 ubiquitin-ligase containing RING, B-box, coiled-coil and six C-terminal NHL domains. Mutations involving NHL and coiled-coil domains result in a pure myopathy (LGMD2H/STM) while the only described mutation in the B-box domain is associated with a multisystemic disorder without myopathy (Bardet-Biedl syndrome type11), suggesting that these domains are involved in distinct processes. Knock-out (T32KO) and knock-in mice carrying the c.1465G > A (p.D489N) involving the NHL domain (T32KI) show alterations in muscle regrowth after atrophy and satellite cells senescence. Here, we present phenotypical description and functional characterization of mutations in the RING, coiled-coil and NHL domains of TRIM32 causing a muscle dystrophy. Reduced levels of TRIM32 protein was observed in all patient muscle studied, regardless of the type of mutation (missense, single amino acid deletion, and frameshift) or the mutated domain. The affected patients presented with variable phenotypes but predominantly proximal weakness. Two patients had symptoms of both muscular dystrophy and Bardet-Biedl syndrome. The muscle magnetic resonance imaging (MRI) pattern is highly variable among patients and families. Primary myoblast culture from these patients demonstrated common findings consistent with reduced proliferation and differentiation, diminished satellite cell pool, accelerated senescence of muscle, and signs of autophagy activation.

Keywords: Muscle dystrophy, TRIM32, E3 ubiquitin-ligase, Proliferation/differentiation, Autophagy

Introduction

Tripartite motif-containing protein 32 (TRIM32) is an E3 ubiquitin ligase, whose activity is contained in the RING finger domain of the tripartite TRIM/RBCC motif (RING, B-box, coiled-coil) [20, 30]. In addition, TRIM32 has six C-terminal NHL domains. The majority of the mutations described in TRIM32 are clustered in the C-terminal NHL domain, which is defined by amino acid sequence homologies to regions of Ncl-1, HT2A and Lin-41 proteins, supporting its role in protein-protein interactions, critical for the ubiquitination process [13, 29, 44]. Mutations involving the NHL and coiled-coil domains are associated with limb-girdle muscular dystrophy 2H (LGMD2H) and sarcotubular myopathy (STM), which are considered as a continuum [15, 21]. Until now, only one mutation has been described involving the B-box domain, resulting in a different multisystemic disorder called Bardet-Biedl syndrome (BBS) type 11 with no skeletal muscle involvement, in an only family with four affecting siblings [7]. No mutations in the RING finger domain have been reported.

Proximal weakness is the characteristic feature of LGMD2H/STM, although other clinical findings, such as facial, axial or distal weakness, can be associated [5, 15, 19, 28, 33, 34, 39, 42]. Pathologically LGMD2H/STM are characterized by segmental vacuolation of the sarcoplasmic reticulum and transverse tubules [42], however vacuoles containing basophilic material consistent with...
autophagic vacuoles have also been observed in the muscle biopsy of these patients [21, 28]. The mutation c.1459G > A/p.D487N in the TRIM32 gene, identified as a founder mutation in Hutterite population, has been the most frequently reported [15], but a recent series of 12 non-Hutterite patients with a TRIM32-related myopathy, with mutations located both in the NHL and coiled-coil domains, has been described [21].

A yeast model has shown that TRIM32 mutations involving the NHL domain introduce conformational changes that impair the interaction properties of the protein, and consequently the ubiquitination process [39]. The most relevant mechanistic studies have been performed in the Trim32 knockout (T32KO) and the knock-in mice carrying the Hutterite mutation (T32KI) [25, 26]. TRIM32, as a ubiquitous E3 ubiquitin ligase, has been demonstrated to promote degradation of several targets [1, 8, 18, 22, 24, 29, 31, 37], so the absence or abnormal function of TRIM32 due to recessive mutations would lead to loss of ubiquitination and accumulation of the TRIM32 substrates. E3 small ubiquitin-related modifier (SUMO) ligase (PIAS4) [1] and N-myc down-regulated protein 2 (NDRG2) have been previously identified as important TRIM32 substrates. Overexpression of PIAS4 is implicated in regulation of cellular senescence [4] and TRIM32-deficient primary myoblasts from T32KO mice have been demonstrated to undergo premature senescence and impaired myogenesis due to accumulation of PIAS4 [23]. On the other hand, NDRG2 overexpression in C2C12 myoblasts reduces cell proliferation and delayed cell cycle withdrawal during differentiation [14, 31]. Altogether, these results coming from cell and animal models, support the hypothesis that TRIM32 is involved in control of myogenesis and that premature senescence underlies myopathy in LGMD2H.

T32KI mice demonstrated that the Hutterite mutation (p.D489N) causes TRIM32 protein degradation, but this finding has not been reported in muscle from patients carrying missense mutations [25]. There is evidence that the EI24 autophagy-associated transmembrane protein is involved in the degradation of RING E3 ligases using the autophagy machinery, establishing a connection between two major protein degradation mechanisms, autophagy and the ubiquitin-proteasome system [11]. However, no specific studies about the role of autophagy in the degradation of TRIM32 have been reported.

We aimed to establish if patients with muscular dystrophy due to TRIM32 mutations show evidence for the pathogenic mechanism postulated in the mouse models. This would provide a potential set of functional assays. We studied the muscle and myoblasts from three families with mutations in the NHL, coiled-coil and RING domains of TRIM32 resulting in a null-phenotype. We demonstrated common findings consistent with premature senescence, reduced myoblast proliferation and differentiation and, in addition, signs of autophagy activation seemingly involved in the degradation of the mutated TRIM32.

Materials and methods

Genetic work-up

DNA was extracted from blood using standard procedures. Patients were studied using next generation sequencing (NGS): patient IV.3/Family A and patient II.2/Family C with a panel of 34 genes associated with autosomal recessive limb-girdle muscular dystrophies, and patient II.3/Family B with a panel of 256 neuromuscular disease genes using HighSeq and NextSeq Illumina platforms. Affected and unaffected relatives of the probands were screened for their family mutations by Sanger sequencing.

Histological studies

Muscle samples were obtained by open muscle biopsies from the biceps brachii muscle of the three patients from Family A (III.2, IV.3 and III.3), two patients from Family B (II.2 and II.3), one patient from Family C (II.2), five aged-matched healthy controls and four age-matched disease controls (LGMD1B, LGMD1C, LGMD2N, NEM6). Frozen muscle sections were stained for standard histological and histochemical techniques including hematoxylin and eosin (H&E) and neonatal myosin heavy chain (MHC-neo). Stained sections were evaluated with an Olympus BX41 (Tokyo, Japan) equipped with a ColorView IIIu camera (Olympus).

Primary cell culture

Myoblasts from Family A (III.2 and IV.3), Family B (II.2 and II.3) and seven aged-matched healthy controls and three age-matched disease controls (LGMD2B, and X-EDMD) were used for the experiments. Fresh muscle samples were minced and cultured in a monolayer. Briefly, the culture medium for the myoblast stage (proliferation medium) contains 75% Dulbecco’s minimal essential medium (DMEM, Invitrogen) and 25% M199 medium (Invitrogen), supplemented with 10% fetal bovine serum (FBS), 10 μg/ml insulin, 2 mM glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml fungizone, 10 ng/ml epidermal growth factor, and 25 ng/ml fibroblast growth factor. To obtain highly purified myoblasts, each 10⁷ cells were mixed with 20 μl of CD56-coated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and incubated at 4 °C for 15 min. Unbound microbeads were removed by washing cells in excess PBS buffer followed by centrifugation at 400×g for 10 min. The cell pellet was resuspended in PBS buffer to a concentration of 2 × 10⁶ cells/ml before
separation on a midiMACS cell separator (Miltenyi Biotec, Bergisch Gladbach, Germany).

Transmission Electron microscopy (TEM)
A piece of muscle from each biopsy and primary myoblast from patients and controls were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 3 h at 4 °C, washed with the same buffer, postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) for 1 h at 4 °C, and then rinsed with distilled water. Samples were immersed in 2% uranyl acetate, dehydrated through a gradient acetone series (50, 70, 90 and 100%), and embedded in Spurr’s resin. Semithin sections (450 nm thickness) were obtained with a glass knife and stained with 1% toluidine blue for muscle fiber/myoblast localization and reorientation using a conventional optic microscope. Once a suitable block face of the selected area was trimmed, ultrathin sections (70 nm) were obtained using an ultramicrotome (Leica UC7) equipped with a diamond knife (Diatome) and collected on 200 mesh copper grids. Sections were viewed with a Zeiss Libra 120 transmission electron microscope (Carl Zeiss NTS GmbH, Oberkochen, Germany).

Scanning Electron microscopy (SEM)
Primary myoblasts from patients and controls were fixed with 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 3 h at 4 °C and postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) for 1 h at 4 °C. Samples were then dehydrated through a graded series of acetone solutions, critical point dried, gold sputtered, and examined with a Zeiss Auriga Field Emission Scanning Electron Microscope (Carl Zeiss NTS GmbH, Oberkochen, Germany).

Immunohistochemical studies
Cultured primary myoblasts from patients and controls were fixed with 4% paraformaldehyde for 30 min, permethylized in 0.2% Triton X-100 for 10 min and incubated in 1% BSA/PBS for 45 min. The following primary antibodies were used: rabbit polyclonal anti-TRIM32 (NBP1–33737) (1:500; Novus Biologicals); rabbit monoclonal anti-Desmin (D93FD5) (1:100; Abcam); mouse monoclonal anti-Ki67 (B56) (1:200; BD Biosciences); mouse monoclonal anti-Myogenin (FD5) (1:100; Abcam); mouse monoclonal anti-Mysin Heavy Chain (A4.1025) (1:500; Millipore); rabbit polyclonal anti-Myosin (D2D11) (1:100; Cell Signaling); rabbit monoclonal anti-LAMP1 (D2D11) (1:1000; Cell Signaling) and rabbit polyclonal anti-GAPDH (1:2000; Sigma-Aldrich). Immunoreactivity was detected with secondary antibodies conjugated to horseradish peroxidase (1:5000; Jackson ImmunoResearch) and developed with SuperSignal West Femto (Thermo Fisher Scientific) using an ImageQuant LAS 4000 MiniGold System (GE Healthcare Life Sciences).

Proliferation and differentiation assays
CD56-positive cells were seeded at 15,000 cells/cm² using proliferation medium. We examined proliferation over a period of time from 0 to 8 days. The average number of cells for each time point (0, 4, and 8 days) was then calculated and the values were used to plot growth curves. When the myoblasts started to fuse, the medium was substituted with one containing 2% of FBS without growth factor to induce differentiation. We
Fig. 1 (See legend on next page.)
measured the fusion index 4 days after medium change by calculating the mean percentage of nuclei in myotubes, relative to the total number of nuclei (myoblasts + myotubes).

**Autophagy blockade experiment**

Bafilomycin A1 (Baf-A1), an autophagosome-lysosome fusion inhibitor, inhibits autophagy by preventing the fusion of the lysosome to the autophagosome [46]. Myoblasts after 4 days in proliferation medium were incubated with 1 μM Baf-A1 (Cayman) for 6 h, followed by lysis and western blot analysis.

**Statistical analysis**

Graphpad Prism software (RRID: SCR_002798) was used to analyze the data using one-way ANOVA. When the ANOVA analysis revealed significant differences, the post hoc Bonferroni’s test was used for pairwise comparisons. When parametric assumptions were not met, Kruskal-Wallis followed by the post hoc Dunn test were used. Data were plotted as mean ± SEM.

**Results**

**Mutations in NHL, coiled-coil and RING domains of TRIM32 are found in patients with a muscular dystrophy**

We studied three independent families of Spanish and Australian origin with a muscular dystrophy (Fig. 1a), and identified four novel TRIM32 mutations located in three different domains; NHL, coiled-coil and RING domains. Patients II.2, II.3 and III.3 from family A were homozygous for TRIM32 c.1771G > A (p.V591M) involving the fourth NHL repeat. None of the six healthy relatives studied from three different generations were homozygous for the mutation, whose frequency in gnomAD was 0.002%. Patients II.1, II.2, II.3 and II.4 from family B were compound heterozygous for c.650 A > G (p.N217S) and c.1701_1703del (p.F568del) mutations, involving the coiled-coil and fourth NHL repeat respectively. The unaffected mother was heterozygous for the c.650 G > A (p.N217S) mutation and the father was not available, thus the mutations were estimated likely to be in trans. Both mutations were very rare in the population (0.002 and 0.0003% in gnomAD respectively). Patients II.2, II.3 and II.4 from Family C were homozygous for a TRIM32 c.115_116insT (p.C39LfsX17) mutation, involving the RING domain (Fig. 1b). Segregation analysis demonstrated that the variant was found in heterozygous state in the rest of the healthy relatives studied from different generations, and was absent from the gnomAD control population.

Distinct clinical and radiological features are identified in all families

All patients from Family A presented with foot drop as the first manifestation in their teens. This was the only symptom for years. Over further time, they developed remarkable ankle contractions. Later, they also developed proximal and distal weakness in lower and upper limbs. The youngest patient (IV.3) showed a more severe progression, with need of support for gait in his thirties (Fig. 1c).

In Family B, there was a remarkable clinical variability. Patient II.3 presented in her twenties with foot drop as the first manifestation in their teens. This was the only symptom for years. Over further time, they developed remarkable ankle contractions. Later, they also developed proximal and distal weakness in lower and upper limbs. The youngest patient (IV.3) showed a more severe progression, with need of support for gait in his thirties (Fig. 1c).

Patients from Family C, presented with limb-girdle muscle weakness with onset between third and fourth decade and later developed distal limb weakness (Fig. 1c). Interestingly, patients II.3 and II.4 presented additional systemic manifestations typically described in BBS including hypogonadism, hearing loss, and behavioral abnormalities (depression and obsessive-compulsive disorder).
No cardiac or respiratory involvement was found in any of the examined patients.

Muscle MRI revealed different patterns of muscle involvement in the three families (Fig. 1d). Family A showed diffused fatty degeneration in the thighs and lower legs. Family B displayed a more focal pattern of fatty replacement mainly involving the biceps femoris and semimembranosus muscle in the thigh and mildly...
Fig. 3 (See legend on next page.)
in the soleus muscle in the lower legs. Interestingly, the asymptomatic patient II.1 did show moderate fat replacement of muscles. Family C showed predominant degeneration of the gluteus muscles, the posterior compartment in the thighs, and the soleus and gastrocnemius muscles in the lower legs.

**TRIM32 gene mutations lead to a reduced TRIM32 protein level**

At present, most TRIM32 reported mutations are clustered in the highly conserved C-terminal NHL domain of TRIM32 and may cause conformational changes in the protein that lead to a substantial decrease in its stability. This hypothesis is supported by the reduced level of TRIM32 found in human fibroblasts isolated from LGMD2H patients carrying the homozgyous p.D487N substitution and in the muscle from the mouse model T32KI (harboring the p.D489N substitution) [1, 25]. Based on these observations, we analyzed the effect of the novel mutations on the presence of TRIM32 in muscle samples from patients. Western blot revealed almost undetectable TRIM32 protein level in TRIM32<sup>C39L</sup>X<sub>17</sub> muscle, which was an expected result because it is a frame-shift mutation resulting in a premature stop codon, which in turn should result in a severely truncated TRIM32 protein. However, we also found a remarkable reduction of TRIM32 level in TRIM32<sup>V591M</sup> and TRIM32<sup>N217S/F568del</sup> myoblasts compared with controls. Data from 14 to 41 independent fields were analyzed per condition. Mean ± SEM; Kruskal-Wallis with Dunn’s multiple comparisons test.

**Mutations in TRIM32 impair proliferation and myogenic differentiation in primary myoblasts**

Data from T32KO mice shows that TRIM32 is necessary for proliferation and differentiation of satellite cells through the regulation of the transcription factor c-Myc [35], and that the loss of TRIM32 function deregulates these processes due to the accumulation of TRIM32 substrates involved in myoblast proliferation and myogenesis [31]. We studied whether loss of protein due to TRIM32 human mutations alter myoblast proliferation in vitro. To address this point, primary myoblasts from patients carrying p.V591M and p.N217S/p.F568del mutations were cultured. The cell proliferation rate (Fig. 3a) and percentage of Ki67<sup>+</sup> cells (Fig. 3b) were significantly lower in mutant myoblasts compared with controls. Next, we investigated if muscle differentiation was also altered when TRIM32 is reduced. The confluent myoblasts were cultured in differentiation medium, in which myoblasts withdraw from the cell cycle, cease to divide, and start to elongate and fuse to form multinucleated myotubes. Myogenin expression (Fig. 4a-b) and fusion index (Fig. 4c) were reduced in mutant myoblasts compared with controls. These results were further supported by western blot in which we found a reduction of the differentiation markers myosin heavy chain and myogenin in TRIM32<sup>V591M</sup> muscle compared with controls (Fig. 4d). TRIM32<sup>C39L</sup>X<sub>17</sub> myoblasts showed an extremely slow growth due to the reduced proliferation that precluded the production of enough cells for these experiments. Taken together, our data suggests that the loss of TRIM32 protein due to different mutations reduced myoblast proliferation and delayed myogenic differentiation.

**TRIM32 mutations in humans lead to premature senescence of myoblasts**

As mentioned, altered myogenesis and premature senescence are postulated to underlie myopathy in LGMD2H. Aging of muscle is characterized by functional impairment, loss of quiescence and reduction of the pool of satellite cells leading to altered regenerative capacity of the muscle [6, 45]. Additional features of senescent cells include overexpression of SA-β-gal [12], and altered morphology [36]. To study whether the reduced cellular growth and myotube formation observed in TRIM32 mutant myoblasts were associated with premature senescence, we analyzed the satellite cells pool, the degree of muscle regeneration and the existence of morphological and metabolic changes in muscle from patients with
Fig. 4 (See legend on next page.)

A

4 days of differentiation

|                | Healthy control | Disease control | Family A/III.2 | Family B/II.3 |
|----------------|-----------------|-----------------|----------------|---------------|
| Desmin         |                 |                 |                |               |
| Myogenin       |                 |                 |                |               |
| Merge (+Topro 3)|                 |                 |                |               |

B

\[
\text{\% Myogenin Cells} \quad \text{Healthy controls} \quad \text{Disease controls} \quad \text{Family A} \quad \text{Family B}
\]

C

\[
\text{Fusion index} \quad \text{Healthy controls} \quad \text{Disease controls} \quad \text{Family A} \quad \text{Family B}
\]

D

\[
\begin{array}{c|cccc}
\text{Muscle} & \text{Ctr1} & \text{Ctr2} & \text{A1/II.3} & \text{A1/III.3} \\
\hline
\text{Myosin} & 250 & 250 & 250 & 250 \\
\text{Myogenin} & 25 & 25 & 25 & 25 \\
\text{GAPDH} & 40 & 40 & 40 & 40 \\
\end{array}
\]

\[
\begin{array}{c|cccc}
\text{Muscle} & \text{Ctr1} & \text{Ctr2} & \text{Ctr3} & \text{C1/II} \\
\hline
\text{Myosin} & 250 & 250 & 250 & 250 \\
\text{Myogenin} & 25 & 25 & 25 & 25 \\
\text{GAPDH} & 40 & 40 & 40 & 40 \\
\end{array}
\]
novel TRIM32 mutations. PAX7 staining (an established
marker for satellite cells in adult skeletal muscle),
showed severe reduction of the satellite cell pool in
TRIM32<sup>V591M</sup> and TRIM32<sup>C39LfsX17</sup> skeletal muscles
compared to controls (Fig. 5a). To evaluate the regenera-
tive activity, muscle sections were stained with an
antibody to MHC-neo, which is expressed in regenerat-
ing myofibers [40]. Unlike the disease control muscle, no
staining of MHC-neo or few scattered positive myofibers
was detected in muscle samples with mutant TRIM32
(Fig. 5b).

Morphological characterization of TRIM32-mutant
myoblasts was examined by SEM, showing that mutant
myoblasts were larger in size and flatter than controls.
In addition, TRIM32-mutant myoblasts had smaller pro-
jections and a reduction in filopodia, which could re-
cess the cellular mobility compared to control
myoblasts (Fig. 5c). To determine possible metabolic
changes of TRIM32-mutant myoblasts, we quantified
the number of cells positively stained for SA-β-gal ac-
tivity. A higher percentage of SA-β-gal positive myoblasts
was observed in TRIM32<sup>V591M</sup> and TRIM32<sup>N217S/F568del</sup>
myoblasts compared with control myoblasts (Fig. 5d).
These results suggest that TRIM32-mutant myoblasts
may undergo premature senescence.

Rimmed vacuoles and signs of autophagy activation are
usual findings in muscle biopsies from patients with
mutations in TRIM32

Histological analysis of the muscle biopsies from patients
showed a severe dystrophic pattern encompassing inter-
nalized nuclei, endomysial fibrosis, and necrotic and atro-
phic myofibers. Small vacuoles containing basophilic
material were observed throughout the sarcoplasm in
scattered myofibers from all muscle biopsies examined,
but no empty vacuoles were identified by optical micros-
copy (Fig. 6a), unlike previously described cases of
TRIM32 mutations [19, 28, 42]. Ultrastructural analysis by
TEM showed the vacuoles are membrane-bound, with
many containing amorphous granular material (Fig. 6b).

The presence of membrane-bound vacuoles containing
cytoplasmic degradation products suggests altered aut-
ophagy. We examined the cytoplasmic content of
TRIM32-mutant myoblasts by TEM, and increased
numbers of lysosomes and autophagic vacuoles were
detected in TRIM32<sup>V591M</sup> and TRIM32<sup>N217S/F568del</sup>
myoblasts compared with controls (Fig. 6c). We observed
numerous electron-dense vacuoles consistent with auto-
lysosomes and many multi-vesicular/lamellated struc-
tures. In addition, immunoblotting for LAMP1, a
lysosomal marker, revealed increased lysosomal content
in TRIM32<sup>V591M</sup> and TRIM32<sup>C39LfsX17</sup> muscle compared
with controls (Fig. 6d). P62/SQSTM1 is a marker of au-
tophagic activity because it directly binds to LC3-II in
the autophagosome membrane. Both LC3-II and P62/
SQSTM1 are selectively degraded by autophagy. West-
ern blot demonstrated a striking reduction of p62/
SQSTM1 level in muscle from the three patients from
family A (Fig. 6e, upper panel), while in the only muscle
sample available from family C was slightly reduced
compared to controls (Fig. 6e, lower panel). Levels of
LC3-II were also reduced in muscles from family A and
C (Fig. 6e, lower panel). On the other hand, patient
myoblasts in culture showed an increase of LC3-II in the
basal state compared to controls, which further increases
when fusion between autophagosomes and lysosomes
was inhibited in the presence of Baf-A1 (Fig. 6f). To-
gether, these results suggest that increased autophagic
flux is present in TRIM32-related myopathy.

Mutated TRIM32 is degraded by autophagy
Previous studies have shown that the EI24
autophagy-associated transmembrane protein is involved
in autophagy-mediated degradation of RING E3 ubiqui-
tin ligases [11]. As TRIM32 is an E3 ubiquitin ligase,
we analyzed whether the degradation of TRIM32 mutated
protein was dependent on autophagy. For this experi-
ment we used TRIM32<sup>V591M</sup> myoblasts. After autophagy
was inhibited using Baf-A1, western blot analysis of pri-
mary myoblasts lysates showed that mutant TRIM32
protein level was efficiently rescued (Fig. 6f). This result
supports that TRIM32<sup>V591M</sup> is degraded via the autoph-
agy pathway.

Discussion
In an effort to establish if the muscle from patients with
muscular dystrophy due to TRIM32 mutations shows
evidence for the pathogenic mechanism postulated from
Fig. 5 (See legend on next page.)
NDRG2 and PIAS4 in skeletal muscle, secondary to the accumulation of the TRIM32 substrates proliferation/differentiation and satellite cell senescence as a protein involved in the control of myogenic cell degradation of the mutated TRIM32. This supports a similar underlying pathomechanism for mutation or missense) and the location within the protein. The type of mutation (frameshift, single amino-acid deletion of TRIM32 protein muscle level, regardless of coiled-coil and RING domains of TRIM32. A common dystrophy due to mutations involving the NHL, muscle and myoblasts from three families with a muscular dystrophy involving the NHL, coiled-coil and RING domains of TRIM32. A common consequence of all the mutations was the remarkable reduction of TRIM32 protein muscle level, regardless of the type of mutation (frameshift, single amino-acid deletion or missense) and the location within the protein. This supports a similar underlying pathomechanism for all of the mutations. We also demonstrated reduced myoblast proliferation/differentiation and premature senescence, reproducing the findings that had been seen in animal models [23, 25, 31, 35]. We have also shown evidence of autophagy activation, probably involved in the degradation of the mutated TRIM32.

Experiments in the T32KO mice pointed at TRIM32 as a protein involved in the control of myogenic cell proliferation/differentiation and satellite cell senescence due to the accumulation of the TRIM32 substrates NDRG2 and PIAS4 in skeletal muscle, secondary to the failure of their ubiquitination by TRIM32 [23, 31]. After exploring these processes in myoblasts with mutations affecting different TRIM32 domains that causes loss of protein, our results identified a significant delay in proliferation and differentiation. The features of premature senescence demonstrated in muscles from patients with TRIM32 mutations, including a reduced pool of satellite cells and increased expression of SA-β-gal, are plausible consequences of the altered myogenic process. An alteration of myogenesis has been described in other hereditary muscle disorders, as a primary mechanism [43] or as a concomitant effect associated with, or in the absence of premature senescence [2, 9, 38]. In the case of TRIM32 the accumulation of several substrates involved in different biological processes and the frequent finding of rimmed vacuoles, support that, in addition to the altered myogenesis, other pathways could be playing a pathogenic role.

The presence of increased amounts of autophagic vacuoles, lysosomes and a high level of LAMP1 in muscle with mutated TRIM32 pointed to an alteration in autophagy. Degradation of p62/SQSTM1 is a widely used marker to monitor autophagic activity because it directly binds to LC3-II in the autophagosome membrane and is degraded by autophagy. Decreased level of p62/SQSTM1 in muscle form TRIM32-myopathy patients supports an increased autophagy. LC3-II is also degraded by the lysosome along with the autophagosome content, so a decrease in LC3-II over time provides an estimate of the autophagic flux. LC3-II in muscle from our patients showed decreased LC3-II, which also supports increased autophagy, but LC3-II amount at a given time point does not necessarily estimate the autophagic activity. However, the increase of LC3-II in mutant myoblast culture after Baf-A1 treatment supports increased autophagic flux. The autophagy in the muscle with TRIM32 mutations could be activated by different triggers. First, it is well established that autophagy is essential to maintain the population of satellite cells and their function [16, 17], and that failure of autophagy in aged satellite cells causes senescence. It has been demonstrated that the experimental induction of senescence leads to mTOR downregulation and autophagy activation [32, 47]. Therefore, the premature senescence in LGMD2H muscles could lead to increased autophagy perhaps offsetting some of the effects of the TRIM32 alteration. On the other hand, the accumulation of substrates that are no longer ubiquitinated due to loss of the mutated TRIM32 protein and therefore not degraded by the proteasome machinery, could activate autophagy as an alternative degradation pathway [41]. Further investigations could clarify this point.

In mature healthy muscle, TRIM32 level is normally low because it seems to be restricted to satellite cells [23, 35]. This makes detecting the protein in skeletal muscle challenging. Nevertheless, we found that the TRIM32 protein level was markedly reduced in skeletal

---

**Fig. 5** TRIM32 mutations seem to lead to premature senescence of myogenic cells. a Immunohistochemistry staining and quantification of Pax7+ satellite cells in skeletal muscle from family A patients (n = 2), family C patient (n = 1), healthy controls (n = 5) and disease controls (LGMD2B, LGMD1C, LGMD2N, NEM6) (n = 4). Immunostaining for collagen type IV (red) to show the muscle fibers, Pax7 (green) to show the satellite cells and with Topro 3 staining for the nuclei (blue). Quantification of Pax7+ cells revealed a significant reduction in the number of satellite cells in TRIM32V591M and TRIM32N217S/F568del muscles compared with controls. Data from 8 to 31 independent fields were analyzed per condition. Mean ± SEM; Kruskal-Wallis with Dunn’s multiple comparisons test. Scale bar, 50 μm. b Immunohistochemical staining of MHC-neo of skeletal muscle from family A patients, family B patients, healthy control and disease control (LGMD1B) revealed a large number of positive regenerating fibers in the disease control. In contrast, TRIM32 patients showed no positive cells (patients A/II.2, A/IV.3 and B/II.2) or, at most, few scattered positive cells (patients B/II.3 and C/II.2). Scale bar, 100 μm. c SEM images of myoblasts at 5 days growing in proliferation medium from AIV.3 and B/II.3 patients, and healthy controls. TRIM32V591M and TRIM32N217S/F568del myoblasts were larger than control myoblasts. Higher magnification showed a reduction in the size of projections and number of filopodia of TRIM32V591M and TRIM32N217S/F568del myoblasts compared to control myoblasts. Scale bars, 100 μm: lower magnification view; 2 μm: hyper magnification view. d Immunofluorescence staining and quantification of the percentage of SA-β-gal+ cells in human myoblasts after 10 days growing in proliferation medium from family A patients (n = 2), family B patients (n = 2) and healthy controls (n = 2). A higher increment of SA-β-gal+ cells was observed in TRIM32V591M and TRIM32N217S/F568del myoblast cultures compared to controls, supporting a premature senescence in the muscles with TRIM32 altered function. Data from 8 independent fields were analyzed per condition. Mean ± SEM; One-way ANOVA with Tukey’s multiple comparisons test. Scale bar, 100 μm.
Fig. 6 (See legend on next page.)
muscle from patients with the missense mutations, single amino acid deletion, or frameshift mutation compared to controls. Data about TRIM32 protein level in muscle of patients with TRIM32 mutations is scarce. Expected loss of protein by immunoblot was reported in a patient compound heterozygous for a large deletion that removes the whole TRIM32 gene and a frameshifting mutation, while heterozygous relatives for either of the mutations showed normal TRIM32 level [5], which is the same as we found in TRIM32C39LfsX17 muscle. To date, no reported data exist about the level of TRIM32 in muscle from patients with TRIM32 missense mutations. The T32KI mouse model carrying the Hutterite missense mutation p.D489N shows a severe reduction of TRIM32 by immunoblot, and the same neuromuscular phenotype as Trim32-null mice [25]. Our results of profound reduction of TRIM32 level associated with novel missense mutations are fully consistent with previous studies demonstrating a markedly reduced amount of TRIM32 in primary fibroblasts cultured from LGMD2H patients homozygous for the p.D487N substitution [1]. This finding suggests that the mutant TRIM32 proteins might undergo degradation. Thus, reduced level of the protein detected by immunoblot could support the pathogenic role of future novel TRIM32 missense mutations classified as variants of unknown significance (VUS), in the appropriate clinical context [21].

Mutations in the NHL, B-box and coiled-coil domains of TRIM32 have been previously described [7, 21], but to date mutations in the RING domain had not been reported. Here, we report that all the mutations are associated with a loss of protein leading to a muscular dystrophy. The presenting features were highly variable regarding severity, proximal/distal distribution and muscle MRI pattern, but with common histological features in all cases. Different phenotypes produced by mutations in TRIM32, even in the same region of the gene, has similarly been reported in other myopathies associated with mutation in other genes such as MYH7 [27]. Strikingly, two of the three patients with the mutation p.C39LfsX17 in the RING domain presented, in addition to the muscle dystrophy, hypogonadism, hearing loss and behavioral abnormalities, symptoms typically described in the BBS previously associated with a mutation in the B-box domain [3, 10]. BBS is a rare ciliopathy characterized by multisystemic manifestations (retinal degeneration, obesity, polydactyly, renal abnormalities, hypogonadism, behavioral abnormalities, among others), but no muscle weakness. Only one family with BBS and TRIM32 mutation in the B-box domain has been described, and symptoms of BBS have not been previously described in patients with TRIM32 muscular dystrophy. The variable phenotypes in patients with mutations in TRIM32 are most likely explained by modifying factors that have yet to be identified and would have to be studied in as large a cohort of TRIM32 patients as could be assembled.

Conclusion
Our results demonstrate a common pathogenic pathway in the development of muscular dystrophy associated to TRIM32 mutations which lead to loss or reduction of the protein. The main effect of TRIM32 mutations is consistent with alterations of myogenesis which induce a diminished pool of satellite cells and accelerate the senescence of skeletal muscle. We also demonstrated signs of autophagy activation, that could be the response to different triggers but probably collaborating in the pathogenic process. We also provide clinical evidence of TRIM32-related myopathy patients presenting muscular weakness together with BBS clinical manifestations, but to elucidate responsible factors additional studies must be carried out. The identification of an increasing number of VUS, especially missense variants, complicates the
diagnostic process of genetic disorders. In the case of TRIM32 mutations, besides myoblast culture to demonstrate reduced proliferation and differentiation, which is not always available, we propose immunoblot to characterize the effect of novel candidate pathogenic variants on TRIM32 protein level.

Abbreviations
Baf-A1: Bafilomycin A1; BBS: Bardet-Biedl syndrome; EDMD: Emery-Dreifuss muscular dystrophy; LGMD: Limb-girdle muscular dystrophy; MRI: Magnetic resonance imaging; NDRG2: N-myc down-regulated protein 2; NEM: nemalin myopathy; PIA54: E3 small ubiquitin-related modifier (SUMO) ligase; SEM: Scanning Electron Microscopy; SMC: Sarcomeric myopathy; T32KO: Trim32 knock-out; T32KO: Trim32 knockout; TEM: Transmission Electron Microscopy; TRIM32: Tripartite motif-containing protein 32; VUS: Variants of unknown signification

Acknowledgments
We thank Diego Ruano (Instituto de Biomedicina de Sevilla) for kind donation of the antibody against the LC3 and p62SQSTM1 protein.

Funding
Supported in part by grants from the Health Institute Carlos III and FEDER a way to achieve Europe (PI16-01843 to CP, JR15/00042 to MC-S), the Fundación Progreso y Salud, Junta de Andalucía (PI-0085-2016 to JLN-G), and Australian National Health and Medical Research Council (NHMRC) Fellowships (APP1122952 and APP1117510 to GR and NGL).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions
CP and ES designed the study, ES performed immunoblots and function studies, cell culture, satellite cells and myogenesis analysis. CP, MC-S, AC, ALP, and PL assessed the patients and relatives, provided clinical information and collected biological samples. ER, RJ and JMD processed and studied muscle biopsies. CP and MC-S analyzed the radiological findings. CP, MC-S, AC, ALP, and PL wrote the initial manuscript. All authors contributed to the final version of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was approved by the Institutional Research Ethic Committee at Hospital Universitario Virgen del Rocío in Seville (Spain). Written informed consent was received from participants, prior to inclusion in the study, for genetic studies, for muscle biopsies, and for pictures appearing in the manuscript.

Consent for publication
The authors declare that written informed consents for publication of images relating to individual patients were obtained.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Neuromuscular Disorders Unit, Department of Neurology, Instituto de Biomedicina de Sevilla, Hospital U. Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain. 2Centro de Investigación Biomédica en Red sobre Enfermedades Neuromusculares de Nuestro Siglo (CIBERNED), Madrid, Spain. 3Centre for Medical Research, University of Western Australia, Harry Perkins Institute of Medical Research, Perth, Australia. 4Department of Neurophysiology, Hospital U. Virgen del Rocío/ Institute of Biomedicine of Seville (IBIS), Seville, Spain. 5Neuromuscular Unit, Hospital Virgen de las Nieves, Granada, Spain. 6Neurology Department, University Hospital Marqués de Valdecilla (IDIVAL), Santander, Cantabria, Spain. 7PathWest Laboratory Medicine WA, Section of Neuropathology, Royal Perth Hospital, Perth, WA, Australia. 8Centre for Comparative Genomics, Murdoch University, Perth 6150, Australia. 9Percion Institute for Neurological and Translational Science, University of Western Australia, Nedlands, Australia. 10Neurology Department, Health in Code S.L., A Coruña, Spain. 11Department of Medical Physiology and Biophysics, Instituto de Biomedicina de Sevilla, Hospital U. Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.

Received: 16 January 2019 Accepted: 20 February 2019

References
1. Albor A, El-Hizawi S, Horn EJ, Laelderich M, Fosk P, Wrognemann K, Kulesz-Martin M (2006) The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation and regulates UVB-induced keratinocyte apoptosis through NF-kappab. J Biol Chem 281:25850–25866. https://doi.org/10.1074/jbc. M061555200
2. Andre LM, Ausems CRM, Wansink DG, Wieringa B (2018) Abnormalities in skeletal muscle Myogenesis, growth, and Regeneration in Myotonic Dystrophy. Front Neurol 9:368. https://doi.org/10.3389/fneur.2018.00368
3. Beales PL, Etcioglu N, Woolf AS, Parker D, Flinter FA (1999) New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet 36:437–446
4. Bischof O, Schwamborn K, Locke M, Eilen M, Althberg G, Uschen R, Hagen M, Huebner A, Lochmuller H, Wrognemann K et al (2009) Intragenic deletion of TRIM52 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum Mutat. 30:E831–E844. https://doi.org/10.1002/humu.21063
5. Borg K, Stucka R, Locke M, Eilen M, Althberg G, Uschen R, Hagen M, Huebner A, Lochmuller H, Wrognemann K et al (2009) Intragenic deletion of TRIM52 in compound heterozygotes with sarcotubular myopathy/LGMD2H. Hum Mutat. 30:E831–E844. https://doi.org/10.1002/humu.21063
6. Chakkalakal JV, Jones KM, Basson MA, Brack AS (2012) The aged niche disrupts muscle stem cell quiescence. Nature 490:355–360. https://doi.org/10.1038/nature11438
7. Chiang AP, Beck JS, Yen HJ, Tayeh MK, Scheetz TE, Swiderski RE, Nishimura DY, Braun TA, Kim KY, Huang J et al (2006) Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). Proc Natl Acad Sci U S A 103:6287–6292. https://doi.org/10.1073/pnas.060158103
8. Cohen S, Zhai B, Gypi SP, Goldberg Al (2012) Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J Cell Biol 196:575–589. https://doi.org/10.1083/jcb.201110067
9. de Luna N, Gallardo E, Soriano M, Dominguez-Perles R, de la Torre C, Rojas-Garcia R, Garcia-Verdugo JM, Ilia I (2006) Absence of dysferlin alters myogenin expression and delays human muscle differentiation “in vitro”. J Biol Chem 281:17092–17098. https://doi.org/10.1074/jbc.M601885200
10. Deveault C, Billingsley G, Duncan JL, Jin J, Theal R, Vincent A, Fieggen KJ, Gerth C, Noondeh I, Traboulsi El et al (2011) BBS genotype-phenotype assessment of a multietnic patient cohort calls for a revision of the disease definition. Hum Mutat. 32:610–619. https://doi.org/10.1002/humu.21480
11. Devkota S, Jeong H, Kim Y, Ali M, Roh JL, Hwang D, Lee HW (2016) Functional characterization of ED4-induced autophagy in the degradation of RING-domain E3 ligases. Autophagy 12:2038–2053. https://doi.org/10.1080/15548627.2016.1217371
12. Dmity GP, Lee K, Basile G, Acosta M, Scott G, Roskeley C, Medrano EE, Linskens M, Rubelj I, al P-SO (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363–9367. https://doi.org/10.1073/pnas.92.9363–9367
13. E-Husseini AE, Vincent SR (1999) Cloning and characterization of a novel RING finger protein that interacts with class V myosins. J Biol Chem 274:19771–19777
14. Follerita VC, Prior MJ, Supik K, Carey K, Segal D, Jones S, Swinton C, Martin S, Cameron-Smith D, Walder KR (2009) NDRG1, a novel regulator of myoblast proliferation, is regulated by anabolic and catabolic factors. J Physiol 587:1619–1634. https://doi.org/10.1113/jphysiol.2008.167882
15. Fosk P, Weiler T, Nylén E, Sudha T, Greenberg CR, Morgan K, Fujisawa TM, Wrognemann K (2002) Limb-girdle muscular dystrophy type 2H associated
with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 70:663–672. https://doi.org/10.1086/339083
16. Garcia-Prat L, Martinez-Vicente M, Perdiguero E, Orlet O, Rodriguez-Urbeja J, Rebollo E, Ruiz-Bonilla V, Gutara S, Ballestar E, Serrano AL et al (2016) Autophagy maintains stemness by preventing senescence. Nature 529:37–42. https://doi.org/10.1038/nature16167
17. Garcia-Prat L, Munoz-Canoves P, Martinez-Vicente M (2016) Dysfunctional autophagy is a driver of muscle stem cell functional decline with aging. Autophagy 12:612–613. https://doi.org/10.1080/1554822X.2016.1143211
18. Gonzalez-Cano L, Hille AL, Fuertes-Alvarez S, Marques MM, Blanch A, Ian RW, Irwin MS, Schwamborn JC, Marin MC (2013) Regulatory feedback loop between TF33 and TRIM32. Cell Death Dis 4:e704. https://doi.org/10.1038/cddis.2013.224
19. Jerusalem F, Engel AG, Gomez MR (1973) Sarcotubular myopathy: A newly recognized, benign, congenital, familial muscle disease. Neurology 23:897–906
20. Joazeiro CA, Weissman AM (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549–552
21. Johnson K, De Rieder W, Topf A, Bentol M, Phillips L, De Jonghe P, Baets J, Deconinck T, Rakovec S, Stojarovic V, al P (2018) Extending the clinical and mutational spectrum of TRIM32-related myopathies in a non-Hutterite population. J Neurol, Neurosurg, Psychiatry. https://doi.org/10.1136/jnnp-2018-318088
22. Kano S, Miyajima N, Fukuda S, Hatakeyama S (2008) Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. Cancer Res 68:5518–5528. https://doi.org/10.1158/0008-5472-CAN-07-6231
23. Kudryashova E, Kramarov I, Spencer MJ (2012) Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy. J Clin Investig 122:1764–1776. https://doi.org/10.1172/JCI59581
24. Kudryashova E, Kudryashov D, Kramarov I, Spencer MJ (2005) Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquinates actin. J Mol Biol 354:413–424. https://doi.org/10.1016/j.jmb.2005.09.068
25. Kudryashova E, Stuay A, Molchnova E, Cannon SC, Spencer MJ (2011) The common missense mutation D489N in TRIM32 causing limb-girdle muscular dystrophy 2H leads to loss of the mutated protein in knock-in mice resulting in a Trim32-null phenotype. Hum Mol Genet 20:3925–3932. https://doi.org/10.1093/hmg/ddt311
26. Kudryashova E, Wu L, Hivton LA, Spencer MJ (2009) Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component. Hum Mol Genet 18:1353–1367. https://doi.org/10.1093/hmg/ddp036
27. Lamont PJ, Wallefeld W, Hilton-Jones D, Udd B, Argov Z, Barboi AC, Bonnemann C, Boycott KM, Bushby K, Connolly AM et al (2014) Novel mutations widen the phenotypic spectrum of slow skeletal/beta-cardiac myosin (MYH7) distal myopathy. Hum Mut 35:868–879. https://doi.org/10.1002/humu.22553
28. Liewluck T, Tracy JA, Sorenson EJ, Engel AG (2013) Scapuloperoneal muscular dystrophy phenotype due to TRIM32-sarcotubular myopathy in a South Dakota Hutterite. Neuromuscul Disord : NMD 23:133
29. Locke M, Tinsley CL, Benson MA, Blake DJ (2009) TRIM32 is an E3 ubiquitin ligase for dysbindin. Hum Mol Genet 18:2344–2358. https://doi.org/10.1093/hmg/ddv049
30. Micale L, Chaignat E, Fusco C, Reymond A, Merla G (2012) The tripartite component. Hum Mol Genet 18:1353
31. Mokhonova EI, Avliyakulov NK, Kramerova I, Kudryashova E, Haykinson MJ, Locke M, Tinsley CL, Benson MA, Blake DJ (2009) TRIM32 is an E3 ubiquitin ligase mutated in limb-girdle muscular dystrophy 2H. Hum Mutat 29:240–247. https://doi.org/10.1002/humu.20863
32. Narita S, Gorza L, Schiaffino S (1982) Fetal myosin heavy chains in regenerating muscle. Nature 298:294–296
33. Nectoux J, de Cid R, Baulande S, Leturcq F, Urtizberea JA, Penisson-Besnier I, Ruy YS, Lee Y, Lee KW, Hwang CY, Maeng JS, Kim PH, Seo YS, You KH, Song B, Kwon KS (2011) TRIM32 protein sensitizes cells to tumor necrosis factor (TNFalpha)-induced apoptosis via its RING domain-dependent E3 ligase activity against X-linked inhibitor of apoptosis (XIAP). J Biol Chem 286: 25729–25738. https://doi.org/10.1074/jbc.M111.241893
34. Sacco A, Mourkoti F, Tran R, Choi J, Llevellyn M, Kraft P, Shkrelli M, Delp S, Pomerantz JH, Artandi SE et al (2010) Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143:1059–1071. https://doi.org/10.1016/j.cell.2010.11.039
35. Servian-Morilla E, Takeuchi H, Lee TV, Clarimon J, Mavillard F, Area-Gomez E, Rivas E, Nieto-Gonzalez JL, Rivera MC, Cabrera-Serrano M et al (2016) A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. EMBO Mol Med 8:1339–1349. https://doi.org/10.15252/emmm.201505815
36. Schoser B (2009) Physiology, pathophysiology and diagnostic significance of autophagic changes in skeletal muscle tissue—towards the enigma of rimmed and rounded vacuoles. Clin Neuropathol 28:59–70
37. Schoser BG, Froik P, Engel AG, Klutzny U, Lochmuller H, Wroegken K (2005) Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol 57:591–595. https://doi.org/10.1002/ana.20441
38. Servian-Morilla E, Takeuchi H, Lee TV, Clarimon J, Mavillard F, Area-Gomez E, Rivas E, Nieto-Gonzalez JL, Rivera MC, Cabrera-Serrano M et al (2016) A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. EMBO Mol Med 8:1339–1349. https://doi.org/10.15252/emmm.201505815
39. Shack FJ, Ruvkun G (1998) A novel repeat domain that is often associated with RING finger and B-box motifs. Trends Biochem Sci 23:474–475
40. Sousa-Victor P, Gutarra S, Garcia-Prat L, Rodriguez-Urbeja J, Orlet O, Ruiz Bonilla V, Jardi M, Ballestar E, Gonzalez S, Serrano AL et al (2014) Geriatric muscle stem cells switch reversible quiescence into senescence. Nature 506: 316–321. https://doi.org/10.1038/nature13013
41. Yamamoto A, Tagawa Y, Yoshimori T, Moribe Y, Fujiki H, Tashiro Y (1998) Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H4-II-E cells. Cell Struct Funct 23:333–42
42. Young AR, Nairn M (2010) Connecting autophagy to senescence in pathophysiology. Curr Opin Cell Biol 22:234–240. https://doi.org/10.1016/j.ceb.2009.12.005

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions